![](https://endpts.com/wp-content/uploads/2022/07/Jay-Luly-Enanta-Pharmaceuticals.jpg)
Jay Luly, Enanta Pharmaceuticals CEO
Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M
Enanta Pharmaceuticals is selling off royalty payments from its AbbVie-partnered drug Mavyret, its biggest revenue driver, to a Canadian pension plan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.